within Pharmacolibrary.Drugs.ATC.L;

model L01DB09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0013099999999999997,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.325,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DB09</td></tr><td>route:</td><td>intravesical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Valrubicin is a semisynthetic anthracycline derivative used as an antineoplastic agent, primarily for the intravesical treatment of Bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ of the urinary bladder. It is approved for this indication and is not recommended for systemic administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data are reported for adults with BCG-refractory carcinoma in situ of the bladder following intravesical administration.</p><h4>References</h4><ol><li><p>Onrust, SV, &amp; Lamb, HM (1999). Valrubicin. <i>Drugs &amp; aging</i> 15(1) 69–76. DOI:<a href=\"https://doi.org/10.2165/00002512-199915010-00006\">10.2165/00002512-199915010-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10459733/\">https://pubmed.ncbi.nlm.nih.gov/10459733</a></p></li><li><p>Porten, SP, et al., &amp; Greene, KL (2015). Intravesical chemotherapy in non-muscle-invasive bladder cancer. <i>Indian journal of urology : IJU : journal of the Urological Society of India</i> 31(4) 297–303. DOI:<a href=\"https://doi.org/10.4103/0970-1591.166446\">10.4103/0970-1591.166446</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26604440/\">https://pubmed.ncbi.nlm.nih.gov/26604440</a></p></li><li><p>Patterson, AL, et al., &amp; Gulfo, J (2000). Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. <i>Urology</i> 56(2) 232–235. DOI:<a href=\"https://doi.org/10.1016/s0090-4295(00)00654-3\">10.1016/s0090-4295(00)00654-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10925084/\">https://pubmed.ncbi.nlm.nih.gov/10925084</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DB09;
